Flash Finance

Syncom Formulations (India) LimitedSYNCOMFCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹21.95
MCap ₹2,063 Cr · P/E 1.2
Syncom Formulations (India) Limited — Stock analysis & AI research Syncom Formulations (India) Limited — Seasonality — best & worst months Syncom Formulations (India) Limited — Technical indicators & charts Syncom Formulations (India) Limited — Technical setup — score, trend, support & resistance Syncom Formulations (India) Limited — Live exchange announcements
📈 MACD Bearish Crossover📈 Strong Trend Stocks (ADX > 25)📈 Relative Strength Leaders📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹126 Cr
Sales · Jun 2026
+7.4% YoY
₹26 Cr
Operating Profit · Jun 2026
+65.8% YoY
20.9%
OPM % · Jun 2026
+54.8% YoY
₹25 Cr
Net Profit · Jun 2026
+57.7% YoY
₹0.26
EPS · Jun 2026
+23.8% YoY

📝 Syncom Formulations (India) Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Syncom Formulations (India) Limited reported revenue of ₹126 crore for the quarter ended June 2026 (Q1 FY27), up 7.4% from ₹117 crore in the same quarter last year, and down 7.0% sequentially over the March 2026 quarter.

Net profit rose 57.7% year-on-year to ₹25 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹0.26.

Operating profit stood at ₹26 crore — an operating margin (OPM) of 20.9%, compared with 13.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Syncom Formulations (India) Limited posted revenue of ₹12,539 crore, a growth of 2566.9% over FY25, with a net profit of ₹1,720 crore (up 3386.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹12,547 crore with a net profit of ₹1,729 crore.

Valuation snapshot

At the current price of ₹21.95, SYNCOMF has a market capitalisation of ₹2,063 crore and a trailing P/E of about 1.2.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 8th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 50.57%, foreign institutional investors (FIIs) 2.22%, public shareholders 47.20% of Syncom Formulations (India) Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,063 Cr
Current Price ?
₹21.9
P/E ?
1.19below ind
Industry P/E ?
21.30
P/B ?
4.97
P/S ?
0.16
P/FCF ?
44.85
Enterprise Value ?
₹2,064 Cr
EV/EBITDA ?
1.08
PEG ?
0.02
Earnings Yield ?
85.7%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹12,547 Cr
OPM ?
15.2%
Profit after tax (TTM) ?
₹1,729 Cr
EPS (TTM) ?
₹18.39
ROCE ?
27.0%
ROE ?
416.6%
ROA ?
323.8%
Growth
Sales — latest qtr ?
₹126 Cr
PAT — latest qtr ?
₹25 Cr
YoY qtr sales growth ?
7.4%
YoY qtr profit growth ?
57.7%
Sales growth (3y) ?
30%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
57%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹1 Cr
Debt to Equity ?
0.00
Interest Coverage ?
65.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
50.57%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
63.0%
Return 6 months ?
53.5%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 5768606673758710612814911712,172115135126 +7.4% -7.0%
Operating Profit 66699910121518161,840212226 +65.8% +19.1%
Other Income 272423144765256158 +29.7% -47.8%
Interest 1111010000026000 -2.5% —
Depreciation 11111111111135122 +14.9% -23.0%
Profit Before Tax 6106891010151723202,204253432 +58.9% -5.1%
Net Profit 4847778111318161,660192525 +57.7% -0.6%
EPS 0.060.090.070.070.080.100.110.120.140.160.210.180.230.270.26 +23.8% -3.7%
OPM % 10.3% 8.9% 10.8% 13.9% 12.7% 12.6% 12.1% 11.3% 11.7% 11.9% 13.5% 15.1% 18.4% 16.3% 20.9% +54.8% +28.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹470 Cr ₹12,539 Cr ₹12,547 Cr +2566.9%
Operating Profit ₹55 Cr ₹1,899 Cr ₹1,910 Cr +3339.0%
OPM % 11.75% 15.15% 15.22% +28.9%
NPM % 10.49% 13.72% 13.78% +30.8%
Other Income ₹16 Cr ₹552 Cr ₹553 Cr +3293.1%
Depreciation ₹5 Cr ₹140 Cr ₹140 Cr +2946.0%
Interest ₹1 Cr ₹27 Cr ₹27 Cr +3971.2%
EBIT ₹51 Cr ₹1,759 Cr ₹1,770 Cr +3374.6%
PBT ₹65 Cr ₹2,283 Cr ₹2,295 Cr +3399.1%
Tax ₹8 Cr ₹554 Cr ₹557 Cr +6764.6%
Net Profit ₹49 Cr ₹1,720 Cr ₹1,729 Cr +3386.8%
EPS ₹0.53 ₹0.89 ₹0.94 +67.9%
Material Cost ₹153 Cr ₹6,310 Cr ₹6,312 Cr +4023.1%
Employee Cost ₹25 Cr ₹1,706 Cr ₹1,708 Cr +6830.2%
Extraordinary Items ₹0 Cr ₹0 Cr ₹0 Cr +403.7%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 94949494 +0.0%
Reserves 162194248321 +29.4%
Borrowings 837251 -80.0%
Other Liabilities 394467117 +74.6%
Total Liabilities 378405413534 +29.3%
Fixed Assets 91120125184 +47.2%
CWIP 26000 —
Investments 646693109 +17.2%
Other Assets 197219196241 +23.0%
Total Assets 378405413534 +29.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 11-62358 +152.2%
Cash from Investing Activity -4583-18-51 -183.3%
Cash from Financing Activity 35-15-68-3 +95.6%
Net Cash Flow 162-634 +106.3%
Free Cash Flow -10-141346 +253.8%
CFO/OP 86%7%70%105% +50.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1241448582 -3.5%
Inventory Days 55494981 +65.3%
Days Payable 53565196 +88.2%
Cash Conversion Cycle 1261378368 -18.1%
Working Capital Days -45195164 +72.6%
ROCE % 10%11%19%27% +42.1%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 50.57%50.57%50.57%50.57%50.57%50.57% +0.0%
FIIs 0.41%0.10%0.26%0.21%0.35%2.22% +534.3%
Public 49.02%49.33%49.17%49.23%49.08%47.20% -3.8%
No. of Shareholders 4,71,0664,57,3644,42,2804,31,6904,22,1144,18,465 -0.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Syncom Formulations (India) Limited's revenue in Q1 FY27?
Syncom Formulations (India) Limited reported revenue of ₹126 crore for the quarter ended June 2026 (Q1 FY27), up 7.4% from ₹117 crore in the same quarter last year, and down 7.0% sequentially over the March 2026 quarter.
What was Syncom Formulations (India) Limited's net profit in Q1 FY27?
Net profit rose 57.7% year-on-year to ₹25 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹0.26.
What is SYNCOMF's market capitalisation and P/E ratio?
At the current price of ₹21.95, SYNCOMF has a market capitalisation of ₹2,063 crore and a trailing P/E of about 1.2.
Who owns Syncom Formulations (India) Limited? (shareholding pattern)
As of Sep 2026, promoters held 50.57%, foreign institutional investors (FIIs) 2.22%, public shareholders 47.20% of Syncom Formulations (India) Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI